% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Mair:298982,
      author       = {M. J. Mair and S. Hartenbach and E. Tomasich and S. L. N.
                      Maas and S. A. Bosch and G. Widhalm and F. Eckert and F.
                      Sahm$^*$ and J. A. Hainfellner and M. Hartenbach and A. S.
                      Berghoff and M. Preusser and N. L. Albert$^*$},
      title        = {{E}xpression of {SSTR}2a, {FAP}, {HER}2 and {HER}3 as
                      potential radionuclide therapy targets in higher-grade
                      meningioma.},
      journal      = {European journal of nuclear medicine and molecular imaging},
      volume       = {52},
      number       = {8},
      issn         = {1619-7070},
      address      = {Heidelberg [u.a.]},
      publisher    = {Springer-Verl.},
      reportid     = {DKFZ-2025-00402},
      pages        = {2771-2781},
      year         = {2025},
      note         = {2025 Jul;52(8):2771-2781},
      abstract     = {High-grade meningiomas have high recurrence rates and
                      limited prognosis. Radioligand therapies are approved in
                      extracranial malignancies, but their value in brain tumours
                      including meningiomas is unclear, as data on target
                      expression is scarce.CNS WHO grade 2 and 3 meningioma
                      samples were immunohistochemically stained for somatostatin
                      receptor 2a (SSTR2a), fibroblast activation protein (FAP),
                      and human epidermal growth factor receptors 2/3 (HER2/HER3).
                      Target expression was correlated with (epi-)genetic tumour
                      subtyping by DNA methylation analysis, genetic alterations,
                      and survival.Meningioma samples of 58 patients were
                      included. SSTR2a expression (membranous/cytoplasmic) was
                      observed in 43/55 $(78.2\%),$ and FAP expression in 15/58
                      $(25.9\%)$ evaluable samples, with HER2 and HER3 expression
                      in one specimen each $(1.7\%).$ Membranous SSTR2a expression
                      was strong in 18 $(32.7\%),$ intermediate in 12 $(21.8\%),$
                      and weak in 11 $(20.0\%)$ samples. While SSTR2a expression
                      was more homogenous and mainly seen in regions with higher
                      cellularity, FAP immunoreactivity was predominantly seen in
                      tumour stroma and regions of lower cellularity. SSTR2a
                      immunoreactivity was associated with TRAF7 wildtype status
                      (p = 0.034). FAP expression was more frequent in meningiomas
                      of CNS WHO grade 3 (vs. CNS WHO 2; p < 0.001), and samples
                      with NF2 mutations (p = 0.032) or CDKN2A/B deletions (p =
                      0.013) compared to wildtype. FAP and SSTR2a expression
                      (present vs. absent) were not associated with overall
                      survival (p > 0.05).SSTR2a and FAP are expressed in
                      high-grade meningioma samples to a variable extent, and
                      differences across meningioma subtypes underscore the need
                      for biomarkers to improve patient selection. Spatial
                      heterogeneity of target expression should be considered in
                      radioligand therapy design.},
      keywords     = {Brain tumour (Other) / Fibroblast activating protein
                      (Other) / Meningioma (Other) / Somatostatin receptor (Other)
                      / Theranostics (Other)},
      cin          = {B300 / HD01 / MU01},
      ddc          = {610},
      cid          = {I:(DE-He78)B300-20160331 / I:(DE-He78)HD01-20160331 /
                      I:(DE-He78)MU01-20160331},
      pnm          = {312 - Funktionelle und strukturelle Genomforschung
                      (POF4-312)},
      pid          = {G:(DE-HGF)POF4-312},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:39969538},
      doi          = {10.1007/s00259-025-07075-8},
      url          = {https://inrepo02.dkfz.de/record/298982},
}